CCL22 and allergic asthma: In conclusion, the data from this study demonstrate for the first time that compound 8a as a small molecule antagonist specifically targeting CCR4/CCL17/CCL22/CKLF1 axes effectively attenuates the allergic airways inflammation in a murine model of allergic asthma in vivo.